Stem-like CD8+T cells (Tsl, CD44+TCF1+) have recently been identified as crucial immunocytes for sustaining long-term cancer immunity and responding to immunotherapy, persisting in TdLNs throughout disease progression 14-15. The gene discussed is CD44; the disease is cancer.